Internationale PatientenAktuellesKontakt
UNIVERSITÄTSKLINIKENHACETTEPE
Termin
DE
  1. Home
  2. Ärzte
  3. Ass.-Prof. Dr. Burak Yasin Aktaş
BA

Ass.-Prof. Dr.

Burak Yasin Aktaş

Medical Oncology · Onkologische Klinik

Termin vereinbaren

This page is not yet available in Deutsch. The Turkish version is shown below.

Publications

Source: Hacettepe University academic database (AVESİS) · All publications (52) ↗

Articles 41

  1. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective StudyTaban H., AKSOY S., GÜVEN D. C., AKTAŞ B. Y., Yılmaz F., Aslan F., et al.Medicina (Lithuania), cilt.62, sa.9, 2026 (SCI-Expanded, Scopus)
  2. Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark AnalysisTaban H., AKSOY S., Evlendi Y., AKTAŞ B. Y., Aslan F., ERMAN M.Journal of Clinical Medicine, cilt.15, sa.18, 2026 (SCI-Expanded, Scopus)
  3. Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoidTUNCEL M., KÖKSAL D., DİKMEN E., Şimşir C., Pala A., AKTAŞ B. Y., et al.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.10, ss.5617-5618, 2026 (SCI-Expanded, Scopus)
  4. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyKöylü B., Celayir Ö. M., Muğlu H., Can O., Şen F., Öven B. B., et al.Cancers, cilt.18, sa.12, 2026 (SCI-Expanded, Scopus)
  5. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint InhibitorsŞahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.Journal of Oncological Science, cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin)
  6. The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancerBilgetekin I., Demirci U., Yildirim H. C., Dogan M., Karacin C., Onur İ. D., et al.Clinical and Translational Oncology, 2026 (SCI-Expanded, Scopus)
  7. Biopsychosocial model-based exercise improves muscle strength, proprioception, pain, function, and quality of life in rheumatoid arthritis patients with knee involvement: a randomized controlled clinical tiralAkgoz A., Yakut Y., Tufekci O., AKTAŞ B. Y., Sari E. O., Barlak A., et al.RHEUMATOLOGY INTERNATIONAL, cilt.45, sa.9, 2025 (SCI-Expanded, Scopus)
  8. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancerYILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.BMC CANCER, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
  9. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.Clinical Genitourinary Cancer, cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)
  10. Vaccination attitudes and practices of physicians and nurses in adult oncology settingsOzdemir-Ayduran N., AKTAŞ B. Y., KILIÇKAP S., EKİNCİOĞLU A.JOURNAL OF RESEARCH IN PHARMACY, cilt.28, sa.3, ss.612-620, 2024 (ESCI, Scopus, TRDizin)
  11. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?GÜNER G., AKTAŞ B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., et al.Journal of Cancer Research and Clinical Oncology, cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded, Scopus)
  12. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency AnemiaAKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.Current Oncology, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)
  13. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapyGÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.INTERNATIONAL JOURNAL OF CANCER, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
  14. Emerging treatment strategies in hepatobiliary cancerGÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.Expert Review of Anticancer Therapy, cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus)
  15. Prognosis of Liposarcoma Patients in Modern ERA: Single-Center ExperienceDEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., et al.SOUTH ASIAN JOURNAL OF CANCER, cilt.11, ss.287-292, 2022 (ESCI, Scopus)
  16. Liquid biopsy markers for early diagnosis of brain metastasis patients with breast cancer by metabolomicsOzer O., NEMUTLU E., REÇBER T., Eylem C. C., AKTAŞ B. Y., KIR S., et al.EUROPEAN JOURNAL OF MASS SPECTROMETRY, cilt.28, sa.1-2, ss.56-64, 2022 (SCI-Expanded, Scopus)
  17. Pazopanib-induced chylothorax in a patient with renal cell carcinomaKÖYLÜ B., TEKİN F., AKTAŞ B. Y., KILIÇKAP S., KÖKSAL D.ANTI-CANCER DRUGS, cilt.33, sa.1, 2022 (SCI-Expanded, Scopus)
  18. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving ImmunotherapyYILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
  19. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experienceDiker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.FUTURE ONCOLOGY, cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus)
  20. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitorsGÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.BIOMARKERS IN MEDICINE, cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus)
  21. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded, Scopus)
  22. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.CUREUS, cilt.13, sa.6, 2021 (ESCI)
  23. The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).Bilgetekin I., Dogan M., Karacin C., Basal F. B., Esin E., Ucar G., et al.JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)
  24. Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative AnalysisAkbulut D., Yuksel S., Kircali E., AKTAŞ B. Y., Kaygusuz G., Saglam A., et al.MODERN PATHOLOGY, cilt.34, ss.796-797, 2021 (SCI-Expanded, Scopus)
  25. Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative AnalysisAkbulut D., Yuksel S., Kircali E., AKTAŞ B. Y., Kaygusuz G., Saglam A., et al.LABORATORY INVESTIGATION, cilt.101, ss.796-797, 2021 (SCI-Expanded, Scopus)
  26. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experienceDiker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.CANCER RESEARCH, cilt.81, sa.4, 2021 (SCI-Expanded, Scopus)
  27. Cancer incidence in Behcet's diseaseGÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEN B., AKTAŞ B. Y., KİRAZ S., et al.IRISH JOURNAL OF MEDICAL SCIENCE, cilt.189, sa.4, ss.1209-1214, 2020 (SCI-Expanded, Scopus)
  28. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study DesignGÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.CLINICAL COLORECTAL CANCER, cilt.19, sa.3, 2020 (SCI-Expanded, Scopus)
  29. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)
  30. Cancer incidence in Behcet's Disease.Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)
  31. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implicationsGÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.FUTURE ONCOLOGY, cilt.16, sa.9, ss.497-506, 2020 (SCI-Expanded, Scopus)
  32. Complete responses to two different anti-PD1 agents in a metastatic melanoma patientKILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.26, sa.2, ss.496-499, 2020 (SCI-Expanded, Scopus)
  33. Vitamin D Supplementation and Prevention of Type 2 DiabetesAKTAŞ B. Y., Aktas O. O.NEW ENGLAND JOURNAL OF MEDICINE, cilt.381, sa.18, ss.1784, 2019 (SCI-Expanded, Scopus)
  34. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapyAKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.19, sa.7, ss.589-601, 2019 (SCI-Expanded, Scopus)
  35. Successful Treatment of Amyloid A-Type Amyloidosis Due to Behcet Disease With TocilizumabİLBAY A., ERDEN A., SARI A., ARMAĞAN B., AKTAŞ B. Y., BÖLEK E. Ç., et al.JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, cilt.25, sa.4, 2019 (SCI-Expanded, Scopus)
  36. Evaluation of cancer risk in patients with periodontal diseasesGuven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.3, ss.826-831, 2019 (SCI-Expanded, Scopus, TRDizin)
  37. Mortality Facts in Internal Medicine Wards: A Descriptive Study froma University HospitalÇALIK BAŞARAN N., AKTAŞ B. Y., ŞENER Y. Z., CEYLAN S., YEKEDÜZ E., BAŞPINAR B., et al.Acta Medica, cilt.49, sa.4, ss.6-13, 2018 (TRDizin)
  38. Impact of Exopolysaccharides (EPSs) of Lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa).SUNGUR T., ASLIM B., Karaaslan C., AKTAS B. Y.Anaerobe, cilt.47, ss.137-144, 2017 (SCI-Expanded, Scopus)
  39. Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral CenterŞENER Y. Z., AKTAŞ B. Y., Erden A., KILIÇ L., Armagan B., İNKAYA A. Ç., et al.ARTHRITIS & RHEUMATOLOGY, cilt.67, 2015 (SCI-Expanded, Scopus)
  40. Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life ResultsKALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., et al.ARTHRITIS & RHEUMATOLOGY, cilt.67, 2015 (SCI-Expanded, Scopus)
  41. Kliniko-patolojik olgu tart›flmas›:Sistemik lupus eritematosusAKTAŞ B. Y., KALYONCU U., İNKAYA A. Ç., TUNCER M. A., ARSAVA E. M., KARLI OĞUZ H. K.RAED dergisi, cilt.6, sa.1, ss.36-41, 2014 (Hakemli Dergi)

Conference papers 10

  1. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapyGÜVEN D. C., Incesu F. G. G., Yildirim H. C., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, cilt.33, (Özet Bildiri)
  2. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology HospitalGuven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
  3. Clinical features and prognosis of patients with liposarcoma: Single-center experience.Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)
  4. Retrospective Investigation of sepsis related inpatient mortalityAKTAŞ B. Y., ÇALIK BAŞARAN N., ŞENER Y. Z., BÖLEK E. Ç., öztürk aktaş ö., ÖZIŞIK L., et al.ECIM, 31 Ağustos - 02 Eylül 2017, (Özet Bildiri)
  5. Retrospektive investigation of sepsis related inpatient mortalityAKTAŞ B. Y., ÇALIK BAŞARAN N., ŞENER Y. Z., BÖLEK E. Ç., ÖZTÜRK AKTAŞ ö., ÖZIŞIK L., et al.16th European Congress of Internal Medicine, 31 Ağustos - 02 Eylül 2017, (Özet Bildiri)
  6. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experienceAKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.
  7. Metastatic Choroidal Melanoma: Single Center ExperienceAKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.
  8. Evaluation of cancer risk in patients with periodontal diseases.GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., et al.
  9. TÜRKIYE’DE METASTATIK MEME KANSERINDE HER2 HEDEFLITEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLILIKVERILERIESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., et al.
  10. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation programAKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.

Kitaplar 1

  1. PATOFİZYOLOJİNİN TEMELLERİDURUSU TANRIÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., et al.PALME YAYINCILIK, 2017

Kontakt

Department
Medical Oncology, Onkologische Klinik

Zuletzt aktualisiert: